Drug Trial Radar · NCT05187793
Study of Efficacy of Different Treatment Regimens of Olokizumab
Last checked: Nov 20, 2026Latest source record: Feb 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
198
Actual
Start
Jul 8, 2021
Primary completion
Oct 31, 2022
Study completion Apr 2023
Sponsor
- Lead sponsor
- R-PharmIndustry
- Sponsor type
- Industry
- Collaborators
- Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor; Group of companies Medsi, JSС
- First posted
- Jan 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation. This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.
Conditions
- COVID-19
Interventions
OlokizumabDrug
Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
Standard therapyDrug
Standard treatment including: * Baricitinib, 4 mg, film coated tablets * Favipiravir, 200 mg, film coated tablets * Dexamethasone IV or IM OR Methylprednisolone IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical recovery rate at day 7Time frame: Up to day 7
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department"
Moscow, Russia
Federal State Budgetary Institution "Central Clinical Hospital with a Polyclinic" of Presidential Administration of the Russian Federation
Moscow, Russia
State Budgetary Healthcare Institution "City Clinical Hospital № 52 of Moscow Healthcare Department"
Moscow, Russia
State Budgetary Healthcare Institution "Infectious Diseases Hospital No. 1 of Moscow Healthcare Department"
Moscow, Russia
State Budgetary healthcare Institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1"
Voronezh, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.